The Effect of Liraglutide on Bone Turnover, Bone Mass and Bone Cell Function

NCT02473809 on ClinicalTrials.gov · last registry update 2018-09-26

Finished October 2017, after enrolling 60 people. Primary outcome, as filed: Change in collagen I cross-linked C-terminal telopeptide measured in serum.

Status: COMPLETED
Phase: P4
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: University of Aarhus
Sponsor type: Other
Enrollment: 60
Started: 2015-08
Primary completion: 2017-10 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in collagen I cross-linked C-terminal telopeptide measured in serum

Conditions studied

Diabetes Complications · Osteoporosis

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.